Diagnos (ADK) AI Stock Analysis

• Market Cap: C$35.65M
• Dividend Yield: N/A
• Average Volume (3M): 342.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: -48.53%
• EPS Growth: -9.66%
• Country: CA
• Employees: 16
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 101,862,976
• 10 Day Avg. Volume: 531,548
• 30 Day Avg. Volume: 342,665
• PEG Ratio: -0.45
• Price to Book (P/B): -6.56
• Price to Sales (P/S): 117.69
• P/FCF Ratio: -9.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: C$0.36 ▲(0.00% Upside)

The score is held down primarily by very weak financial performance (large losses, negative equity, and ongoing cash burn). Technicals are comparatively supportive with an uptrend and positive momentum, but valuation is hindered by loss-making results and no dividend data.

Positive Factors

AI-Powered Diagnostic Tools

Diagnos's focus on AI-powered diagnostic tools positions it well in the growing field of healthcare technology, offering potential for long-term growth as demand for advanced diagnostic solutions increases.

Business Model

The subscription-based business model provides a recurring revenue stream, enhancing financial stability and allowing for continuous product development and customer engagement.

Market Reach

By serving a global market, Diagnos can capitalize on diverse healthcare needs, potentially increasing market share and revenue opportunities across different regions.

Negative Factors

Financial Distress

The company's financial distress, marked by ongoing losses and high leverage, poses significant risks to its long-term viability and ability to invest in growth opportunities.

Cash Flow Challenges

Negative cash flows indicate difficulties in generating cash from operations, which could limit the company's ability to fund new projects and maintain financial health without external support.

Revenue Decline

Declining revenue trends highlight potential issues in market demand or competitive positioning, which could impact the company's ability to sustain growth and profitability.

Diagnos Business Overview & Revenue Model

Company Description

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.

How the Company Makes Money

Diagnos generates revenue primarily through the licensing of its AI diagnostic software and services to healthcare institutions. Their business model includes subscription fees for ongoing access to the CARA platform, which provides continuous updates and support. Additionally, Diagnos may earn revenue through partnerships with healthcare providers and pharmaceutical companies, collaborating on research and development initiatives that integrate their technology. The company may also explore revenue through consulting services, offering training and expertise to clients on how to effectively utilize their AI tools in clinical settings. By expanding its network of partnerships and enhancing its product offerings, Diagnos aims to increase its market share and revenue streams.

Diagnos Financial Statement Overview

Summary

Diagnos exhibits significant financial distress across all major financial statements. The income statement shows ongoing losses, the balance sheet reveals high leverage and negative equity in some years, and cash flows highlight operational cash challenges. The company faces substantial risks that threaten its financial health, necessitating urgent strategic adjustments.

Income Statement

Diagnos has faced significant challenges in its income statement, with consistent negative gross profit margins over the years, indicating that the cost of goods sold exceeds revenue. The net profit margins are deeply negative, reflecting ongoing losses. Revenue has shown volatility, with recent declines from previous periods, further exacerbating financial instability. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet reveals financial stress with high leverage as indicated by the debt-to-equity ratio. Stockholders' equity is negative in some years, pointing to a difficult financial position. The equity ratio is low, indicating a reliance on debt financing. These factors imply potential risks in financial stability and solvency.

Cash Flow

Cash flow analysis shows persistent negative operating cash flows, indicating challenges in generating cash from operations. Free cash flow remains negative, exacerbating liquidity concerns. Financing cash flows are positive, suggesting reliance on external financing to sustain operations. Overall, cash flow management appears strained with little improvement over time.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	79.00K	103.80K	170.16K	438.83K	267.07K	331.52K
Gross Profit	-1.30M	-943.56K	35.80K	-418.30K	-347.53K	-473.45K
EBITDA	-4.09M	-3.56M	-2.45M	-2.10M	-2.45M	-1.93M
Net Income	-4.76M	-4.29M	-3.12M	-2.61M	-2.05M	-3.38M
Balance Sheet
Total Assets	1.17M	3.64M	663.79K	1.54M	1.95M	2.43M
Cash, Cash Equivalents and Short-Term Investments	737.25K	3.24M	219.01K	920.91K	1.36M	1.87M
Total Debt	2.39M	3.07M	3.19M	1.19M	471.68K	337.55K
Total Liabilities	2.71M	3.40M	3.72M	1.66M	818.19K	614.78K
Stockholders Equity	-1.54M	233.11K	-3.05M	-113.51K	1.13M	1.82M
Cash Flow
Free Cash Flow	-4.08M	-3.65M	-2.16M	-2.07M	-1.40M	-2.66M
Operating Cash Flow	-4.06M	-3.64M	-2.15M	-2.04M	-1.36M	-2.64M
Investing Cash Flow	1.82M	-3.11M	-14.02K	503.52K	262.93K	-759.98K
Financing Cash Flow	2.24M	6.62M	2.08M	1.60M	882.82K	3.83M

Diagnos Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.33, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.30 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ADK.

Diagnos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ADK	50 Neutral	C$35.65M	-7.34	―	―	-48.53%	-9.66%
AIDR	48 Neutral	C$64.58M	-4.36	-207.53%	―	―	7.04%
CHS	45 Neutral	C$10.41M	-2.74	―	―	16.04%	-455.38%
UDOC	44 Neutral	C$13.82M	-2.77	―	―	―	48.94%
NARA	42 Neutral	C$8.01M	-1.73	―	―	―	81.01%
DMED	33 Underperform	C$11.46M	-8.27	―	―	―	-67.11%

Diagnos Corporate Events

DIAGNOS Appoints New Chief AI Scientist to Propel Healthcare Innovation

DIAGNOS has appointed Dr. Ismail Ben Ayed as Chief Artificial Intelligence Scientist to drive innovation in healthcare through advanced AI technologies. Dr. Ben Ayed will focus on developing next-generation AI tools for the CARA System, strengthening partnerships, and accelerating the creation of clinically validated AI models to transform preventative healthcare.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.33 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

Diagnos Inc. Closes $4 Million Oversubscribed Private Placement

Diagnos Inc. has successfully closed an oversubscribed $4 million brokered private placement led by Centurion One Capital. The funds will be used to advance regulatory initiatives with Health Canada and the FDA, accelerate product development, and expand commercial deployments, thereby enhancing the company’s ability to deliver long-term value to shareholders.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.33 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

Diagnos Inc. Upsizes Private Placement to $3.65M Amid Strong Demand

Diagnos Inc. has announced an increase in its brokered private placement to $3.65 million, led by Centurion One Capital, due to strong investor demand. The proceeds will be used for regulatory affairs, product development, business development, and general corporate purposes, with the offering expected to close on or around December 3, 2025. This move reflects the company’s strategic efforts to bolster its financial resources and enhance its market position, potentially impacting stakeholders positively by expanding its operational capabilities.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

Diagnos Inc. Extends Stock Warrant Exercise Period

Diagnos Inc. has announced its intention to extend the exercise period of 3,502,931 stock warrants from December 5, 2025, to August 5, 2026, pending approval from the TSX Venture Exchange. This extension maintains the exercise price at $0.40 per common share, potentially providing stakeholders with more time to capitalize on their investments, thereby reinforcing Diagnos’s commitment to its financial strategy and market presence.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

Diagnos Inc. Launches $2 Million Private Placement to Support Growth

Diagnos Inc. has announced a brokered private placement led by Centurion One Capital to raise approximately $2 million through the sale of units, each comprising one common share and one warrant. The proceeds will be used for regulatory affairs, product development, business development, and general corporate purposes, with the offering expected to close by December 3, 2025, pending necessary approvals. The initiative highlights Diagnos’s strategic efforts to bolster its financial resources for operational and developmental enhancements, potentially strengthening its market position and offering opportunities for related parties to participate in the investment.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

DIAGNOS Appoints Philippe Couillard as Chairman Amid Expansion Efforts

DIAGNOS has appointed Dr. Philippe Couillard as the Chairman of its Board of Directors, a move expected to strengthen its governance and leadership. This appointment comes as DIAGNOS advances regulatory approvals for its AI-enabled software product, CARA, in major markets including Canada, the United States, and Saudi Arabia, positioning the company for significant growth.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

DIAGNOS Strengthens Advisory Board with New Appointment

DIAGNOS Inc. has announced the addition of Dr. Pierre-Luc Charlebois to its Advisory Board. Dr. Charlebois, an orthopedic surgeon with expertise in health economics, will join other notable members to provide strategic counsel to DIAGNOS. This move is expected to bolster the company’s growth and strengthen its position in the healthcare industry by leveraging Dr. Charlebois’s knowledge of the Canadian healthcare system and his business acumen.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

Diagnos Inc. Extends Stock Warrant Exercise Period

Diagnos Inc. has announced its intention to extend the exercise period of 1,125,000 stock warrants, initially set to expire on November 9, 2025, to a new date of August 5, 2026, pending approval from the TSX Venture Exchange. This extension aims to provide warrant holders with additional time to exercise their options, potentially impacting the company’s financial strategy and market positioning.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

DIAGNOS to Showcase Growth Potential at Bahamas Summit

DIAGNOS has announced its participation in the Centurion One Capital 3rd Annual Bahamas Summit, where CEO André Larente will present and engage with investors. The event provides a platform for DIAGNOS to showcase its growth potential, supported by recent regulatory advancements, to a global audience of growth investors.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

DIAGNOS Achieves MDSAP Audit Success, Paving Way for Global Expansion

DIAGNOS Inc. has successfully completed its annual surveillance audit under the Medical Device Single Audit Program (MDSAP), confirming full compliance with quality and regulatory standards. This achievement strengthens DIAGNOS’ position in regulatory submissions and supports its mission to aid healthcare professionals in early detection of critical health issues. The renewed certification reflects the company’s commitment to scaling its SaaS-based AI platform globally, aligning with its expanding strategy and accelerating approvals with Health Canada, the FDA, and the SFDA.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.